Biological characterization of a novel class of toll-like receptor 7 agonists designed to have reduced systemic activity.
AuthorsBiffen M, Matsui H, Edwards S, Leishman AJ, Eiho K, Holness E, Satterthwaite G, Doyle I, Wada H, Fraser NJ, Hawkins SL, Aoki M, Tomizawa H, Benjamin AD, Takaku H, McInally T, Murray CM,
JournalBr J Pharmacol
PubMed ID22122192
'BACKGROUND AND PURPOSE Toll-like receptor 7 (TLR7) agonists have potential in the treatment of allergic diseases. However, the therapeutic utility of current low molecular weight TLR7 agonists is limited by their systemic activity, resulting in unwanted side effects. We have developed a series of TLR7-selective ''antedrugs'', including SM-324405 and AZ12441970, ... More